Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss (Q33455840)

26 July 2017

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss (English)

1 reference

26 July 2017

7

Matti Ristola

1 reference

26 July 2017

Ana Milinkovic

4

0 references

Peter Reiss

10

object named as

Peter Reiss

1 reference

26 July 2017

Marit G A van Vonderen

1

1 reference

26 July 2017

Michiel A van Agtmael

2

1 reference

26 July 2017

Elly A M Hassink

3

1 reference

26 July 2017

Kees Brinkman

5

1 reference

26 July 2017

Suzanne E Geerlings

6

1 reference

26 July 2017

Arne van Eeden

8

1 reference

26 July 2017

Sven A Danner

9

1 reference

26 July 2017

MEDICLAS study group

11

1 reference

26 July 2017

language of work or name

English

0 references

publication date

21 May 2009

1 reference

26 July 2017

1 reference

26 July 2017

4

1 reference

26 July 2017

e5647

1 reference

26 July 2017

5

1 reference

Creative Commons Attribution 4.0 International

26 July 2017

start time

21 May 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Cardiovascular risk and body-fat abnormalities in HIV-infected adults

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2682584

Cholesterol and coronary heart disease: predicting risks by levels and ratios

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19479079

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19479079

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0005647

1 reference

26 July 2017

0 references

1 reference

26 July 2017

1 reference